Hidden Impairments During Subarachnoid Haemorrhage Recovery, Description and Evolution of a Newly Described Syndrom (HIDDEN)

February 21, 2024 updated by: Assistance Publique - Hôpitaux de Paris
Descriptive observational study in patients with spontaneous subarachnoid hemorrhage or following aneurysmal rupture to assess the presence of a post-HSA syndrome at 3 months, 6 months and 1 year, and its impact on functional outcome using the Rivermead questionnaire

Study Overview

Detailed Description

Every year, subarachnoid hemorrhage affects 9.1 people per 100,000 worldwide, with a peak between the ages of 50 and 60. Its frequency and relatively young age of onset make it a major source of decline in healthy life years.

Progress over the past thirty years has led to a 57% reduction in mortality, but these figures do not always reflect the day-to-day reality of these patients, for whom recovery remains incomplete in almost half of cases. For example, a third of patients have not returned to work at one year, and of those who have, only half have returned to work full-time. In 2020, a Norwegian team showed that, at one year, a third of patients suffer from a "post-HSA syndrome", as yet little described, but which seems very similar to the post-concussion syndrome experienced by patients after head trauma. In their study, only 3% of patients with this syndrome returned to work at one year. A better understanding of the incidence of this syndrome, as well as its evolution and determinants, is therefore essential.

With this in mind, the investigators chose to assess the presence of post-SAH syndrome at 3 months and its repercussions on return to work, using the Rivermead questionnaire.

Secondly, in view of the prevalence of post-traumatic stress syndrome at 3 years (a quarter of patients), the investigators wished to study the factors determining the presence of post-HSA syndrome and an inability to return to work at 3 months, 6 months, 1 year.

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients aged 18 to 65 who had presented with an episode of spontaneous subarachnoid haemorrhage or aneurysmal rupture, excluding meningeal haemorrhage due to trauma,

Description

Inclusion Criteria:

Patient aged 18 to 65

  • Patient hospitalized in intensive care unit at Hôpital Lariboisière between September 2022 and September 2023 for subarachnoid hemorrhage due to aneurysmal rupture.
  • Patient affiliated to the French social security system
  • Patient expressing no objection

Exclusion Criteria:

  • Motor deficits persisting 1 month after SAH
  • Hospitalization > 1 month
  • Patient does not speak French
  • Patient with diagnosis of neurodegenerative disease.
  • Traumatic meningeal hemorrhage
  • Patients on AME

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patients with subarachnoid hemorrhage
Patients hospitalized in Lariboisière intensive care unit for subarachnoid hemorrhage
self-questionnaire with 16 questions, rated from 0 to 4, giving a total of 0 to 52 points.
Other Names:
  • Rivermead Post-Concussion symptoms questionnaire (RPQ)
49-question self-administered questionnaire covering 12 domains (including work/productivity, mood, social roles, family roles, personality, etc.).
Other Names:
  • qustionnaire
multidimensional, generic scale, i.e. one that assesses health status independently of causal pathology, sex, age and treatment
Other Names:
  • questionnaire
16-question questionnaire with answers rated from 0 to 2 to assess Social reintegration
Other Names:
  • questionnaire
rapid frontal efficiency battery, 6 tests from 0 to 3 on each side
MoCA is a screening test for neurocognitive impairment. It comprises 11 categories scored from 0 to 6 for a total of 0 to 30 points.
8 questions rated from 0 to 1 to assess functional outcome
Other Names:
  • questionnaire
mMRS score from 0 to 4 to assess functional outcome
Other Names:
  • questionnaire
To assess the prevalence of post-traumatic stress using the PCL-5 self-questionnaire. PCL-5 is a 20-item self-administered questionnaire.
Other Names:
  • questionnaire
28-question self-questionnaires to study patients' coping strategies
Other Names:
  • questionnaire

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the presence of post SAH syndrome at 3 months and its impact on return to work using the Rivermead Post-Concussion symptoms questionnaire (RPQ), and its impact on functional outcome.
Time Frame: 3 months

The Rivermead questionnaire is a 16-item self-administered questionnaire, rated from 0 to 4, giving a total of 0 to 52 points.

This scale was created to assess post-concussion syndrome, which in many ways is similar to what patients experience after a SAH.

The higher the score, the greater the difficulties experienced by the patient. A score of 3 or 4 for any of the responses indicates that the patient is incapacitated.

3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
- study the factors determining the presence of a post-HSA syndrome and an inability to return to work at 3 months, 6 months and 1 year
Time Frame: 3 months, 6 months and 1 year,
Quality of life assessed using the SS-QoL questionnaire, specific to stroke patients. Self-questionnaire with 49 questions covering 12 domains (including work/productivity, mood, social roles, family roles, personality).
3 months, 6 months and 1 year,
To study the prevalence of post-traumatic stress in this population
Time Frame: 3 months, 6 months and 1 year,
Assess the prevalence of post-traumatic stress in this population using the PCL-5 self-questionnaire. PCL-5 is a 20-question self-questionnaire.
3 months, 6 months and 1 year,
Study patients' coping strategies in relation to functional recovery using the Brief-Cope self-questionnaire
Time Frame: 3 months, 6 months and 1 year,
Brief-Cope self-questionnaire (28-question self-questionnaires).
3 months, 6 months and 1 year,

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2024

Primary Completion (Estimated)

March 1, 2028

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

November 15, 2023

First Submitted That Met QC Criteria

February 21, 2024

First Posted (Estimated)

February 26, 2024

Study Record Updates

Last Update Posted (Estimated)

February 26, 2024

Last Update Submitted That Met QC Criteria

February 21, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intracranial Hemorrhages

Clinical Trials on questionnaire

3
Subscribe